September 1992

Long-term Efficacy of Octreotide in the Treatment of Zollinger-Ellison Syndrome

Author Affiliations

From the Department of Surgery, Division of Surgical Oncology, Oregon Health Sciences University, Portland (Drs Mozell, Cramer, and Woltering); the Department of Medicine, Division of Endocrinology, and the Clinical Research Center Core Peptide Laboratory, The Ohio State University, Columbus (Dr O'Dorisio); and the Salem (Ore) Clinic (Dr Mozell).

Arch Surg. 1992;127(9):1019-1026. doi:10.1001/archsurg.1992.01420090023004

• Nine patients with Zollinger-Ellison syndrome were treated with octreotide acetate (100 μg delivered subcutaneously three times daily) and followed up for 1 to 48 months. Serum gastrin levels were obtained at predetermined intervals. All patients had elevated baseline fasting gastrin levels (>150 ng/L [>150 pg/mL]). One month after administration of octreotide, gastrin levels were in the reference range for five (62%) of eight patients, and a mean gastrin suppression rate of 76% was achieved (ie, values were a mean of 76% less than baseline values). One year after administration of octreotide, five (71%) of seven evaluable patients had gastrin levels of less than 200 ng/L (200 pg/mL), and the mean gastrin suppression rate was more than 80% for these seven patients. During the second year, control at these levels was maintained in four patients; one patient continued to have controlled levels for 42 months. Complete symptomatic response occurred in seven patients (78%), and partial response in two patients (22%). All six patients with diarrhea before treatment were cured of it. Octreotide acetate provides efficacious long-term suppression of elevated gastrin levels and excellent symptomatic relief in patients with Zollinger-Ellison syndrome.

(Arch Surg. 1992;127:1019-1026)